Aldea Pharmaceuticals announces closure of $24M Series B equity financing Aldea Pharmaceuticals.

Â.. Aldea Pharmaceuticals announces closure of $24M Series B equity financing Aldea Pharmaceuticals, a ongoing company pioneering novel therapeutics to take care of aldehyde metabolism disorders, today announced that it offers closed a $24 million Series B equity financing. The financing included brand-new investors RusnanoMedInvest and WuXi PharmaTech Corporate Ventures. All previous traders including Canaan Partners and Correlation Ventures participated in the round also. The funding will be utilized to advance Aldea's lead drug applicant, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous AD-6626 in an emergency room setting.An identical study that was performed in Denmark through the 1918 outbreak indicated that during a wave of atypical pneumonia, there was an increase by a factor of 20 in incidence, in comparison with that in preceding years, which implied that influenza was the putative agent.13 Influenza A viruses were in circulation from 1918 through 1957, and similar isolates genetically, most likely representing a laboratory get away, reemerged in 1977 to periodically cocirculate with A subtypes. In 1976, a restricted amount of swine-influenza cases set off an enormous vaccine campaign to regulate a potential pandemic, which fortunately never occurred. However, unlike the problem in 1976, epidemiologic evidence from this outbreak indicates that there were continuous chains of person-to-person transmission for several viral generations.